/
ALZN
$1.16-$0.04 (-3.33%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6M
4M shares
52-week range
$0.84 – $3.60
12% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
12.34%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-10366.84
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $323.4K | $3.7M | $1.1M | $1.3M | $5.2M | $7.4M | $6.5M | $1.4M |
| Operating income | −$898.0K | −$5.0M | −$4.4M | −$5.0M | −$12.3M | −$14.9M | −$9.9M | −$4.5M |
| EBITDA | $7.3K | −$5.0M | −$4.4M | −$5.0M | −$12.3M | −$14.8M | −$9.9M | −$4.4M |
| Net income | −$932.0K | −$4.9M | −$4.4M | −$5.0M | −$12.4M | −$14.9M | −$9.9M | −$4.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -27.71 | -111.56 | -83.56 | -93.78 | -187.31 | -205.97 | -132.33 | -11.32 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $32M | $-2.60 | $-2.60–$-2.60 | 1 |
| 2028 | $133M | $-3.04 | $-3.04–$-3.04 | 1 |
| 2029 | $32M | $-0.86 | $-0.86–$-0.86 | 1 |
| 2030 | $136M | $6.99 | $6.99–$6.99 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.42
Price
$1.16
Implied upside
+540%
Peer comparison
Alzamend Neuro, Inc. Common Stock
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
www.alzamend.com- Employees
- 7
- IPO / List date
- Jun 15, 2021
- HQ
- ATLANTA, GA
Held by traders on TradeandTell
No one on the platform currently holds ALZN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ALZN as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-05-12 | 1-for-9reverse |
| 2024-07-16 | 1-for-10reverse |
| 2023-10-31 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded ALZN yet.
